Health & Nutritaion
Trump Eases Restrictions on Psychedelic Drug Research to Speed Up Therapeutic Use!
1- Trump signed an executive order directing federal agencies to ease restrictions that for years hindered the study of substances such as LSD, MDMA, and psilocybin, with the aim of accelerating research into their effectiveness in treating mental health disorders such as severe depression and PTSD.
2- The order also allocates $50 million for state-level research into ibogaine, a psychedelic compound derived from an African shrub, which has drawn attention for its potential use in treating opioid addiction and other substance abuse disorders.
3- The decision does not immediately reschedule these substances, but it creates a pathway to ease restrictions on compounds advancing through the FDA approval process, which could soon benefit MDMA as it is currently being studied as a potential treatment for PTSD.